Core Insights - The board of Ark Health (06086.HK) noted a recent increase in the company's share price on September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model as a cornerstone for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - Strategic partnerships were established with Innovent Biologics and Otsuka Pharmaceutical to integrate digital health solutions and improve patient outcomes in the growing weight management market in China [1] Summary by Categories - **Share Price Movement** - The board observed a rise in the company's share price on September 12, 2025 [1] - **Product Development** - The company launched the "Xing Shi" large model, which serves as the foundation for five key applications: AI Drug Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search [1] - **Strategic Partnerships** - A partnership with Innovent Biologics was formed to integrate Ark's digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital support [1] - Collaboration with Otsuka Pharmaceutical aims to combine AI technology with Otsuka's innovative drug portfolio to develop comprehensive digital solutions for drug support services and health education programs [1]

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司股東及潛在投資者於買賣股份時務請審慎行事。 本公告乃根據本公司之命令而作出。董事會就本公告之準確性全體及個別承 擔責任。 承董事會命 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 根據上市規則第13.10條作出之公告 本公告乃應香港聯合交易所有限公司（「聯交所」）要求根據聯交所證券上市 規則（「上市規則」）第13.10條作出。方舟云康控股有限公司（「本公司」）董 事會（「董事會」）留意到，本公司股份（「股份」）近期於2025年9月12日在聯 交所的價格有所上升。 董事會亦留意到，本公司就其於2025年9月10日舉行的第十屆H2H醫療服務 生態大會而刊發的新聞稿（「新聞稿」），其中包括若干本公司之最新消息， 包括(i)本公司發佈專有「杏石」大模型（「杏石大模型」）作為其五項旗艦應用 （AI用藥助手、AI健康管家、AI醫生助手、AI學術助手 ...

Core Insights - Fangzhou Jianke has achieved profitability with a revenue of 1.494 billion yuan, marking a 12.9% growth, and a net profit of 12.5 million yuan as of mid-2025 [3] - The company employs a "familiar doctor-patient" model, focusing on relationship reconstruction rather than merely chasing traffic [4][5] - The AI-powered "Xing Shi Medical Model" aims to enhance the efficiency of its H2H (Hospital to Home) healthcare ecosystem [6][9] Company Performance - Fangzhou Jianke's user base has grown to over 52.8 million registered users and 229,000 registered doctors by mid-2025, with a high repurchase rate of 84.7% among paying users [4] - The company’s growth is driven by value-based internal growth, reducing reliance on continuous traffic purchases [5] AI Integration - The "Xing Shi Medical Model" integrates a comprehensive knowledge base from the Chinese Medical Association, covering over 1.1 million articles across 170 core journals [6] - Five core AI products have been launched, creating a collaborative network across medical, patient, and enterprise sectors [7] Efficiency Improvements - The AI Doctor Assistant has saved over 60,000 hours of work for doctors by providing nearly 400,000 technical assists, allowing them to focus on more complex diagnoses [8] - The AI Health Manager has reduced average consultation times by over 70%, significantly enhancing patient experience [8] Future Vision - By 2025, the company aims to integrate AI assistants into daily medical practices, with daily usage exceeding 100,000 times [10] - The ultimate goal is to establish "Fangzhou Medical Smart Cloud" by 2027, serving as an authoritative clinical decision standard across the industry [10]

Core Viewpoint - Ark Health (06086) has seen a significant stock price increase following the announcement of a strategic partnership with Innovent Biologics to enhance AI-driven chronic disease management solutions [1] Group 1: Stock Performance - Ark Health's stock rose over 7% during trading, with a current increase of 6.65%, reaching HKD 4.65, and a trading volume of HKD 28.54 million [1] Group 2: Strategic Partnership - On September 10, Ark Health signed a strategic cooperation agreement with Innovent Biologics at the 10th H2H Medical Service Ecosystem Conference [1] - The partnership aims to leverage Ark Health's AI technology and industry experience to transform the management process for chronic disease patients, creating a personalized and integrated health management experience [1] Group 3: AI-Driven Services - The collaboration will focus on integrating innovative treatment solutions with AI-driven health management, particularly in the "AI + Weight Loss" service sector [1] - In the pharmaceutical service area, the AI medication assistant will provide 24/7 online consultation, medication inquiries, and support for obesity patients, breaking traditional service limitations [1] - The AI health manager will serve as a constant health management partner, offering personalized medication guidance, service reminders, report interpretation, and educational resources, enhancing patient health literacy and self-management capabilities [1]

Core Viewpoint - Ark Health (06086) has seen a stock price increase of over 7%, currently trading at 4.65 HKD, following the announcement of a strategic partnership with Innovent Biologics to enhance chronic disease management through AI technology [1] Group 1: Strategic Partnership - Ark Health signed a strategic cooperation agreement with Innovent Biologics at the 10th H2H Medical Service Ecosystem Conference on September 10 [1] - The partnership aims to leverage Ark Health's AI technology and industry experience to reshape the full-cycle management process for chronic disease patients [1] - Both companies will work together to integrate innovative treatment solutions with AI-driven health management [1] Group 2: AI-Driven Services - The collaboration will focus on creating a new service paradigm in the "AI + Weight Loss" sector [1] - In the pharmaceutical service area, the AI medication assistant will provide 24/7 online consultation, medication inquiries, and support for obesity patients without waiting time [1] - The AI health manager will serve as a round-the-clock health management partner, offering personalized medication guidance, service reminders, and educational resources to enhance patient self-management capabilities [1]

Core Insights - Ark Health's release of the "Xing Shi Medical Model" represents a significant advancement in chronic disease management, addressing key industry challenges such as low efficiency and insufficient service precision [1][4] - The model integrates various intelligent agents to form a comprehensive service team, enhancing the overall chronic disease management process [4][6] Company Developments - The "Xing Shi Medical Model" is described as a "super digital brain" that incorporates capabilities like image and voice recognition, natural language understanding, and extensive medical knowledge storage [4] - The model's performance is at the State-of-the-Art (SOTA) level, allowing it to effectively aggregate five intelligent agents for a complete service coverage in chronic disease management [4] - Ark Health has developed five core AI products to support doctors, patients, and industry partners, including AI Medication Finder and AI Health Manager, which enhance the efficiency of internet medical services [4][5] Product Innovations - The "OpenEvidence" tool, powered by the Xing Shi model, serves as a clinical decision support system, providing rapid voice responses to medical inquiries, thus improving usability for busy clinicians [5][6] - The AI Academic Assistant can generate comparative reports on medical guidelines in real-time, showcasing its analytical and reasoning capabilities [5][6] Industry Context - The release aligns with the Chinese government's "Artificial Intelligence +" initiative, which aims to empower various sectors, including healthcare, highlighting the importance of technology in improving public health [6] - Ark Health's commitment to innovation in chronic disease management is evident in its strategic roadmap, which includes the integration of AI technologies and the development of a self-researched medical model by 2025 [6]

Core Insights - The strategic partnership between Fangzhou Jianke and Innovent Biologics aims to integrate AI-driven chronic disease management with innovative drug development in the metabolic disease sector, contributing to the "Healthy China 2030" initiative [1][2]. Group 1: Strategic Collaboration - Fangzhou Jianke and Innovent Biologics signed a strategic cooperation agreement to leverage their respective strengths in AI and drug innovation [1][4]. - The collaboration focuses on addressing the growing obesity and metabolic disease market in China, which is projected to reach $14.9 billion (approximately 106.2 billion RMB) by 2030 [2]. Group 2: Market Context - The Chinese weight management market is becoming a significant public health issue, with government initiatives like the "Weight Management Year" program set to launch in June 2024 [2]. - Major pharmaceutical companies are actively positioning themselves to capture market share in this burgeoning sector, emphasizing the need for differentiated solutions and business models [2]. Group 3: Technological and Product Innovations - Fangzhou Jianke plans to enhance chronic disease management through its AI technology and a comprehensive health management ecosystem, featuring five AI products designed to support patients throughout their care journey [3][5]. - Innovent Biologics has developed 16 commercialized products and over 30 product pipelines, with its new weight loss drug, Mazdutide, showing significant efficacy in weight reduction and improvement of various health indicators [3][5]. Group 4: Future Outlook - The partnership aims to create a new service paradigm in the "AI + weight management" space, providing 24/7 online consultation and personalized health management services to patients [5]. - Both companies are committed to enhancing the accessibility and efficiency of chronic disease management services in China, ultimately improving patient outcomes [5].

Core Viewpoint - Fangzhou Inc. has entered a strategic partnership with Innovent Biologics to integrate AI-driven digital health services with innovative therapies for metabolic diseases and weight management, aiming to enhance patient outcomes in chronic disease care [1][2][4]. Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [10]. - Innovent Biologics specializes in developing and commercializing innovative therapies across various medical fields, including oncology, cardiovascular, and metabolic diseases [9]. Partnership Details - The partnership will combine Fangzhou's AI-enabled "H2H" digital healthcare ecosystem with Innovent's pipeline of novel therapies for diabetes and obesity, creating a new model that integrates AI technology with personalized services [2][4]. - The initial focus of the collaboration will be on diabetes and obesity, utilizing Fangzhou's "XS Core" AI large language model to power five key products aimed at delivering personalized digital care [4][6]. Market Context - China's weight management market is rapidly growing, with JPMorgan estimating that the market for weight management drugs could reach USD 14.9 billion by 2030 [2]. - The Chinese government has prioritized weight management as a public health issue, launching a three-year "Weight Management Year" campaign in 2024 [3]. Product Highlights - Innovent's Mazdutide therapy has shown significant weight reduction and improvements in health markers such as blood pressure and lipids, and it has been recognized as one of the "Top 10 Most Anticipated Medicines" globally for 2025 [5]. Future Plans - The companies plan to deepen their collaboration in AI-powered health management, aiming to expand access to innovative therapies and improve the quality and efficiency of chronic disease care in China [8].